Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 16%
Hold 47%
Sell 5%
Strong Sell 0%

Bulls say

Incyte is a biopharmaceutical company with a strong focus on discovering and developing small-molecule drugs for various diseases. The company has a robust pipeline, including a market-leading drug, Jakafi, which treats rare blood cancers and has a partnership with Novartis. Incyte also has several other marketed drugs, with a recent FDA approval for its first dermatology product, Opzelura, and upcoming potential approvals for other drugs in its pipeline. With positive financial results and a promising pipeline, Incyte has the potential for significant growth in the future, making it a stock to watch for investors.

Bears say

Incyte is expected to face challenges with its leading drug Jakafi due to competition and potential concerns about its black box warning and cardiometabolic comorbidities in certain patient populations. Despite other promising drugs in its portfolio, such as Olumiant and Monjuvi, the success of its dermatology products, particularly Opzelura for atopic dermatitis and vitiligo, will determine the company's future growth. However, with high payer friction and monitoring requirements, the success of povorcitinib as a bridge between biologics and an alternative for injection-averse patients will be crucial for Incyte's financial performance.

Incyte (INCY) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 16% recommend Buy, 47% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 19 analysts, Incyte (INCY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.